Who are pirfenidone or nintedanib's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pirfenidone Capsules, pirfenidone 8% gel, COL-1620.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pirfenidone-or-nintedanib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

pirfenidone or nintedanib — Competitive Intelligence Brief

pirfenidone or nintedanib (pirfenidone or nintedanib) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifibrotic agent. Area: Pulmonary/Respiratory.

marketed Antifibrotic agent Pirfenidone: TGF-β pathway; Nintedanib: FGFR, VEGFR, PDGFR tyrosine kinases Pulmonary/Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

pirfenidone or nintedanib (pirfenidone or nintedanib) — Hospices Civils de Lyon. Pirfenidone and nintedanib are antifibrotic agents that reduce fibroblast proliferation and collagen deposition to slow lung fibrosis progression.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
pirfenidone or nintedanib TARGET	pirfenidone or nintedanib	Hospices Civils de Lyon	marketed	Antifibrotic agent	Pirfenidone: TGF-β pathway; Nintedanib: FGFR, VEGFR, PDGFR tyrosine kinases
Pirfenidone Capsules	Pirfenidone Capsules	Shanghai Zhongshan Hospital	marketed	Antifibrotic agent	TGF-β pathway; multiple pro-fibrotic cytokines
pirfenidone 8% gel	pirfenidone 8% gel	Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.	phase 3	Antifibrotic agent	TGF-β signaling pathway; fibroblast proliferation
COL-1620	COL-1620	Merck KGaA, Darmstadt, Germany	phase 3	Antifibrotic agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifibrotic agent class)

Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C. · 1 drug in this class
Hospices Civils de Lyon · 1 drug in this class
Merck KGaA, Darmstadt, Germany · 1 drug in this class
Shanghai Zhongshan Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). pirfenidone or nintedanib — Competitive Intelligence Brief. https://druglandscape.com/ci/pirfenidone-or-nintedanib. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab